Dual Checkpoint Blockade Boosts Breast Cancer pCR

Published Date: 06 Aug 2026

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

Read Full News

Latest News

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

Todays Updates

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Todays Updates

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Latest News

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

News All Time

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Transperineal Biopsy IDs Active Surveillance Candidates

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

The Clues Hidden in Failed Prostate Cancer Trials

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Patients With Early-Onset Cancer Unaware of Infertility Risk

Many patients with early-onset cancer say they were never told that treatments could affect their fertility.

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

Programs offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

Germline Profiling May Improve Risk Stratification in t-MNs

A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.

Body Clock Genes Tied to Prostate Radiotherapy Toxicity

Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?

Recommended News For You

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

Pickleball program boosts health and wellness for cancer survivors, study finds

Beyond What Is Visible in Myelofibrosis?

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

Males with early-onset colorectal cancer are at risk, according to a study.

Dual Checkpoint Blockade Boosts Breast Cancer pCR

No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says

Recommended Articles For You

Uncovering the Hidden Symptoms of Parathyroid Cancer in Women 

Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies 

Exploring New Treatment Options for Hemophilia: A Journey into the Unknown 

Cloud-Based Hematology Decision Support Platforms: Transforming Clinical Practice Through Digital Innovation 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.

2.

Extracellular matrix pathway emerges as treatment target for pediatric cancer

3.

BTK Inhibitor Active in Half of Patients With Richter Transformation

4.

Navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia

5.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

1.

Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields

2.

Understanding Granulosa Cell Tumors: Symptoms, Diagnosis, and Treatments"

3.

Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development

4.

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation

5.

Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

2.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

5.

Evidence-Based Oncology

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot